Role of P‑selectin in thromboembolic events in patients with cancer

  • Authors:
    • Lúcio Flávio Barbour Fernandes
    • José Humberto T.G. Fregnani
    • Célia Maria Cássaro Strunz
    • Adriana de Andrade Ramos Nogueira
    • Adhemar Longatto‑Filho
  • View Affiliations

  • Published online on: November 2, 2017     https://doi.org/10.3892/mco.2017.1482
  • Pages: 188-196
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of the present study was to evaluate the role of P‑selectin in patients with cancer with suspected thromboembolic events (TEEs). Patients with cancer have a four times greater risk of developing TEEs. P‑selectin is a glycoprotein that has the function of facilitating the interaction (adhesion) of leukocytes with the endothelium, or with platelets. There is a well‑defined relationship between P‑selectin and thrombosis; however, it is likely that the cut‑off value of P‑selectin for patients with cancer should be considered differently from that of the general population. In the present report, a prospective cross‑sectional study was performed with patients of the Cancer Hospital of Barretos who were suspected of having TEEs. Among the 178 study participants, 167 (93.82%) were suspected of having deep vein thrombosis, while 59 of them (35.33%) were confirmed as such; and 11 (6.18%) were suspected of having pulmonary thromboembolism, while 3 of them were confirmed as such (27.69%). The mean results obtained were: P‑selectin, 25.37 ng/ml; and D‑dimer, 2,181.22 ng/ml. The P‑selectin levels averaged 33.60 ng/ml with the confirmed TEE group compared with 20.40 ng/ml with the unconfirmed TEE group, with a standard deviation of 23.35 compared with 6.92 (P<0.001); and the level of D‑dimer was 4,615.38 ng/ml compared with 977.52 ng/ml, with a standard deviation of 6,460.54 compared with 2,145.50 (P<0.001). Multiple logistic regression adjusted for distant metastases and the Eastern Cooperative Oncology Group (ECOG) score (2,3 and 4) were constructed. The cut‑off value of P‑selectin for patients with cancer was identified to be different from that reported in the literature for the general population, and the models using D‑dimer and P‑selectin therefore have been demonstrated to be a potentially useful tool to be used in a panel of tests to predict TEEs, either independently or in a prediction score.
View References

Related Articles

Journal Cover

January-2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Barbour Fernandes LF, Fregnani JH, Strunz CM, Nogueira Ad and Longatto‑Filho A: Role of P‑selectin in thromboembolic events in patients with cancer. Mol Clin Oncol 8: 188-196, 2018
APA
Barbour Fernandes, L.F., Fregnani, J.H., Strunz, C.M., Nogueira, A.d., & Longatto‑Filho, A. (2018). Role of P‑selectin in thromboembolic events in patients with cancer. Molecular and Clinical Oncology, 8, 188-196. https://doi.org/10.3892/mco.2017.1482
MLA
Barbour Fernandes, L. F., Fregnani, J. H., Strunz, C. M., Nogueira, A. d., Longatto‑Filho, A."Role of P‑selectin in thromboembolic events in patients with cancer". Molecular and Clinical Oncology 8.1 (2018): 188-196.
Chicago
Barbour Fernandes, L. F., Fregnani, J. H., Strunz, C. M., Nogueira, A. d., Longatto‑Filho, A."Role of P‑selectin in thromboembolic events in patients with cancer". Molecular and Clinical Oncology 8, no. 1 (2018): 188-196. https://doi.org/10.3892/mco.2017.1482